Lymphocyte transformation responses to phytohaemagglutinin and pokeweed mitogen in patients at differing stages of HIV infection: are they worth measuring? NLM AIDSLINE Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Lymphocyte transformation responses to phytohaemagglutinin and pokeweed mitogen in patients at differing stages of HIV infection: are they worth measuring?

J Clin Pathol. 1993 Sep;46(9):846-8. Unique Identifier : AIDSLINE MED/94043849
Bansal AS; Moran A; Potter M; Taylor R; Haeney MR; Mandal BK; Department of Immunology, Hope Hospital, Salford.


Abstract: AIMS--To determine whether the routine measurement of lymphocyte transformation responses to mitogenic stimuli provide any information additional to that available from routine T cell CD4 and CD8 analysis in patients with HIV infection. METHODS--The case records of 197 immunologically investigated HIV seropositive patients were reviewed. The influence of disease stage on T lymphocyte subsets and lymphocyte transformation responses (LyTR) to phytohaemagglutinin (PHA) and Pokeweed mitogen was assessed. RESULTS--The median CD3 and CD4 counts and LyTR to PHA and Pokeweed mitogen were highest in patients with persistent generalised lymphadenopathy (PGL) and decreased progressively in the order: asymptomatic patients, those with ARC, those with AIDS. LyTR to PHA was preserved in over 70% of all patients, but the response to Pokeweed mitogen was depressed in 8% of patients with PGL, 34% of asymptomatic patients, 68% of those with ARC and 78% of those with AIDS. Subnormal values of both CD4 + T cells and LyTR to Pokeweed mitogen were more common in patients with ARC and AIDS (68%) than in those who were asymptomatic or had PGL (20%). CONCLUSIONS--CD4 T cell analysis and LyTR to Pokeweed mitogen, but not to PHA, both correlate with disease states in patients with HIV infection.
Keywords: Acquired Immunodeficiency Syndrome/IMMUNOLOGY AIDS-Related Complex/IMMUNOLOGY CD4-CD8 Ratio CD4-Positive T-Lymphocytes/IMMUNOLOGY Female Human HIV Infections/*IMMUNOLOGY Leukocyte Count Lymphocyte Transformation/*IMMUNOLOGY Male Phytohemagglutinins/*IMMUNOLOGY Pokeweed Mitogens/*IMMUNOLOGY T-Lymphocyte Subsets/IMMUNOLOGY JOURNAL ARTICLEKWDacquiredimmunodeficiencysyndrome/immunologyaids-relatedcomplex/immunologycd4-cd8ratiocd4-positivet-lymphocytes/immunologyfemalehumanhivinfections/KWDimmunologyleukocytecountlymphocytetransformation/KWDimmunologymalephytohemagglutinins/KWDimmunologypokeweedmitogens/KWDimmunologyt-lymphocytesubsets/immunologyjournalarticle
940228
M9420105

Copyright © 1994 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .